BioMarin sees FY23 EPS under new method of $1.80-$2.05, consensus $1.61

Sees FY23 revenue $2.375B-$2.5B, consensus $2.58B. "Beginning with the first quarter of 2023, the company defines Non-GAAP Income as GAAP Net Income excluding amortization of intangible assets, stock-based compensation expense, and certain other specified items. Reflecting this change in the company’s full year 2022 financial results as detailed above would have lowered the company’s full year 2022 Non-GAAP Income by $73.8M and its full year 2022 Non-GAAP diluted earnings per share by $0.38. The company is also introducing a new Non-GAAP financial measure, Non-GAAP Diluted EPS, which is defined as Non-GAAP Income divided by Non-GAAP diluted shares outstanding." The full-year 2023 ROCTAVIAN revenue guidance range represents global revenue estimates and assumes a U.S. approval in 2023, regardless of approval timing, the company noted.